Xuriden Approval History
- FDA approved: Yes (First approved September 4th, 2015)
- Brand name: Xuriden
- Generic name: uridine triacetate
- Dosage form: Oral Granules
- Company: Wellstat Therapeutics Corporation
- Treatment for: Hereditary Orotic Aciduria
Xuriden (uridine triacetate) is an orally administered pyrimidine analog uridine replacement product for the treatment of patients with hereditary orotic aciduria.Hereditary orotic aciduria is a rare autosomal recessive disorder caused by a defective or deficient enzyme resulting in the body being unable to normally synthesize uridine, a necessary component of ribonucleic acid (RNA). The condition is characterized by retarded growth, anemia and excessive excretion of orotic acid in the urine. Xuriden works as a uridine replacement product. It is supplied in the form oral granules which are administered once daily, mixed with soft food, or in milk or infant formula. Xuriden was well tolerated in clinical trials and no side effects were observed in patients who received treatment for up to nine months.
Development History and FDA Approval Process for Xuriden
|Sep 4, 2015||FDA Approves Xuriden (uridine triacetate) to Treat Hereditary Orotic Aciduria|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.